BridgeMD
Compares treatment options for Lung Neoplasms
Official title Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field
ClinicalTrials.gov ID: NCT04944563
What this study is testing
- What it's testing
- This study aims to investigate whether segmentectomy had non-inferiority long-term oncological effects (disease-free survival and overall survival) compared with lobectomy in the treatment of patients with early-stage non-small cell lung cancer ≤ 2 cm in the middle third of lung field.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Patient aged 18-75 years old;
- 6 mm ≤ tumor size ≤ 20 mm;
- 0.25 \< CTR \< 1;
- Center of tumor located in the middle third of the lung field;
- ECOG score of 0,1 or 2;
You likely can't join if
- The tumor nodule is located in right middle lobe;
- A history of other malignancies in the last 5 years (exclusion of early-staged thyroid cancer);
- Have received preoperative anti-tumor therapy, including prior chemotherapy, radiation therapy, target therapy and so on;
- A serious mental illness;
- Pregnant and lactating women;
- Congestive heart failure, myocardial infarction, severe stenosis of coronary artery within recent 6 months;
See the full eligibility criteria
- Patient aged 18-75 years old;
- 6 mm ≤ tumor size ≤ 20 mm;
- 0.25 \< CTR \< 1;
- Center of tumor located in the middle third of the lung field;
- ECOG score of 0,1 or 2;
- Lung function (FEV1 ≥ 1 L and ≥ 70%);
- Both lung segmentectomy and lobectomy could achieve R0 resection;
- No serious cardiopulmonary complications, and could withstand both lung segmentectomy and lobectomy;
- No hilus pulmonis and mediastinal lymph node metastasis and no distant metastasis;
- Single tumor nodule or the concomitant nodule \< microinvasive tumor;
- Written informed consent.
- The tumor nodule is located in right middle lobe;
- A history of other malignancies in the last 5 years (exclusion of early-staged thyroid cancer);
- Have received preoperative anti-tumor therapy, including prior chemotherapy, radiation therapy, target therapy and so on;
- A serious mental illness;
- Pregnant and lactating women;
- Congestive heart failure, myocardial infarction, severe stenosis of coronary artery within recent 6 months;
- With the history of cerebral infarction or cerebral hemorrhage within 6 months;
- With the history of sustained systemic corticosteroid therapy within 1 month;
- The predicted surgical margin is less than 2 cm or the maximum diameter of the tumor at the 3D-CTBA
- Other unsuitable situations;
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.